HC Wainwright Boosts Earnings Estimates for Editas Medicine

Key Points

• HC Wainwright raised its Editas Medicine earnings forecasts, projecting narrower losses of $0.66 per share for fiscal 2026 and $0.70 for fiscal 2027, while still expecting the company to remain unprofitable.
• Editas reported a quarterly loss of $0.15 per share, beating the consensus estimate of $0.27, and generated $11.89 million in revenue versus expectations of $2.85 million.
• Analyst sentiment is mixed but leans positive: Editas has a consensus “Moderate Buy” rating and a $5.40 target price, while shares recently traded at $2.88 and insiders have been selling stock.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Editas Medicine in a report released on Thursday, August 6th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.33). The consensus estimate for Editas Medicine's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Editas Medicine's Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.66) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.70) EPS.

Several other analysts have also issued reports on EDIT. Weiss Ratings reiterated a "sell (e+)" rating on shares of Editas Medicine in a report on Friday, July 17th. Wall Street Zen upgraded Editas Medicine from a "sell" rating to a "hold" rating in a research note on Saturday. TD Cowen reissued a "buy" rating on shares of Editas Medicine in a report on Wednesday, May 27th. Finally, Chardan Capital raised their price target on Editas Medicine from $3.50 to $4.00 and gave the company a "buy" rating in a report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Editas Medicine presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.40.

Editas Medicine Price Performance

Shares of EDIT stock opened at $2.88 on Monday. The company has a market capitalization of $281.98 million, a price-to-earnings ratio of -3.84 and a beta of 2.14. The firm has a fifty day moving average of $2.90 and a 200-day moving average of $2.64. Editas Medicine has a 12-month low of $1.66 and a 12-month high of $4.54.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $11.89 million during the quarter, compared to analyst estimates of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%.

Insider Transactions at Editas Medicine

In other news, CEO Gilmore Neil O'neill sold 15,380 shares of the business's stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $2.70, for a total transaction of $41,526.00. Following the completion of the sale, the chief executive officer owned 248,313 shares in the company, valued at $670,445.10. The trade was a 5.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,503 shares of company stock worth $57,910 in the last three months. Company insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Editas Medicine

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Editas Medicine in the second quarter valued at about $34,312,000. Pallas Capital Advisors LLC acquired a new stake in Editas Medicine in the 2nd quarter worth about $38,000. Deutsche Bank AG bought a new stake in Editas Medicine in the 2nd quarter valued at about $322,000. SCS Capital Management LLC bought a new stake in Editas Medicine in the 2nd quarter valued at about $113,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Editas Medicine during the 2nd quarter worth approximately $851,000. Institutional investors and hedge funds own 71.90% of the company's stock.

Key Stories Impacting Editas Medicine

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts. The firm improved its FY2026 EPS estimate to a loss of $0.66 from $1.04 and its FY2027 estimate to a loss of $0.70 from $1.15. Quarterly estimates were also raised, including Q3 2026 to a loss of $0.20 from $0.33 and Q4 2026 to a loss of $0.08 from $0.13. These revisions suggest analysts expect Editas Medicine’s losses to narrow more quickly than previously anticipated. HC Wainwright earnings estimates
• Positive Sentiment: Forecasts for 2027 also improved. HC Wainwright raised its estimates for the first three quarters of 2027, with Q1 and Q2 losses now projected at $0.20 per share and Q3 at $0.21, compared with prior estimates of $0.33 and $0.34 for the quarters revised in the reports. The more favorable outlook could improve investor sentiment toward the gene-editing company’s cost and revenue trajectory. Editas Medicine analyst estimates
• Neutral Sentiment: Wall Street Zen upgraded Editas Medicine to “Hold.” The rating indicates a neutral stance rather than a bullish recommendation, suggesting the shares may be fairly valued while investors await additional clinical, commercial, or financial progress. Editas Medicine upgraded to Hold
• Negative Sentiment: Editas is still expected to remain unprofitable. Even after the revisions, HC Wainwright forecasts losses through 2027, and the broader current-year consensus remains a loss of approximately $1.03 per share. Investors should therefore view the estimate increases as a reduction in expected losses, not evidence that the company has reached profitability.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source